SCHEMBL20156144

SCHEMBL20156144

CC(C)c1ccc(C(C)(C)c2cnc3cc(CC(C)c4ncc5ccccc5n4)ccc3n2)nn1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20230871 0.82 HTR2A (0.37) —
SCHEMBL20093302 0.78 SMN1; SMN2 (0.34) —
SCHEMBL25118500 0.78 HTR2A (0.37) —
SCHEMBL19954911 0.78 HTR2A (0.38) —
SCHEMBL22825592 0.71 CYP1A2 (0.50) —
SCHEMBL20155649 0.69 HTR2A (0.41) —
SCHEMBL20098087 0.68 NPSR1 (0.32) —
SCHEMBL21250494 0.65 TRPV1 (0.36) —
SCHEMBL29805014 0.64 CNR2 (0.32) —
SCHEMBL23841158 0.64 HTR2A (0.38) —

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10647713-B2 TYK2 inhibitors and uses thereof NIMBUS LAKSHMI, INC. (US) 2020-05-12 — — US disclosed
US-20180134700-A1 TYK2 INHIBITORS AND USES THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2018-05-17 — — US disclosed
Send feedback